Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Cytomel (Liothyronine) Regret, Stopping, and Restarting: What Real Patients and Clinicians Say

By
Published Updated Last reviewed
6 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Drug / liothyronine sodium (Cytomel), synthetic T3 [1]
  • Biological half-life / about 2.5 days [1]
  • Adult starting dose / 25 mcg once daily; 5 mcg if older or cardiac disease [1]
  • Usual maintenance / 25 to 75 mcg once daily [1]
  • Label restart instruction / after cardiovascular symptoms, withhold or reduce for one week, then restart lower [1]
  • Guideline position / ATA 2014 recommended against routine T4/T3 combination; 2023 UK consensus allows selected shared decision [2][3]
  • Boxed warning / not for obesity or weight loss [1]

What the trials show about benefit

A 2006 meta-analysis of 11 randomized trials with 1,216 adults found no difference between T4/T3 combination and T4 alone for pain, depression, anxiety, fatigue, quality of life, body weight or lipids, and adverse events did not differ [4]. A 2021 joint ATA/BTA/ETA consensus noted that 14 trials had not shown a consistent benefit of combination therapy, although patients who report benefit keep interest in it alive. The group agreed there was equipoise for a new trial [5].

What the label says about starting, switching and restarting

The label says to start adults with hypothyroidism at 25 mcg once daily and raise by 25 mcg every 1 or 2 weeks if needed. For older adults or people with underlying cardiac disease it says to start at 5 mcg once daily and raise in 5 mcg steps. It gives usual maintenance as 25 to 75 mcg once daily [1].

When switching a patient to Cytomel, the label says to discontinue levothyroxine, start Cytomel at a low dosage and increase gradually. It notes that Cytomel has a rapid onset and that residual effects of the other preparation may persist for several weeks [1].

For restarting, the label says that if cardiovascular symptoms develop or worsen, the dose should be reduced or withheld for one week and restarted at a lower dose. It does not name a number for that lower dose [1]. In pregnancy, the label says Cytomel should not be discontinued [1]. In overdose, it says to reduce the dose or temporarily discontinue it [1].

For monitoring, the label says TSH is checked periodically in primary hypothyroidism. In secondary or tertiary hypothyroidism TSH is not a reliable measure of dose adequacy, and serum T3 is used [1].

How long T3 acts

The label gives a biological half-life of about 2.5 days for T3. Onset of activity occurs within a few hours and maximum pharmacologic response within 2 or 3 days [1]. The label says T4 binds more tightly to serum proteins than T3, which partly explains T4's longer half-life [1].

What clinicians' guidelines say

The American Thyroid Association 2014 guideline kept levothyroxine as the standard of care. It recommended against routine T4/T3 combination therapy (weak recommendation, moderate-quality evidence) and found insufficient evidence to support routine trials of combination therapy outside formal studies [2]. A 2023 UK consensus says a trial may be warranted for some adults with confirmed overt hypothyroidism and persistent symptoms despite optimized levothyroxine, as a shared decision [3].

A 2025 review of 52 studies found that in randomized trials (n=2,128) adverse events with combination therapy were not statistically different from monotherapy (relative risk 1.22, 95% CI 0.66 to 2.25). The cohort data are observational, so confounding is possible, and the authors say more studies are needed [6]. The label's boxed warning says thyroid hormones including Cytomel should not be used for obesity or weight loss [1].

Frequently asked questions

What does the Cytomel label say about stopping?
The label says that if cardiovascular symptoms develop or worsen, the dose should be reduced or withheld for one week and restarted at a lower dose. It says Cytomel should not be discontinued during pregnancy, and that the dose should be reduced or temporarily discontinued if signs of overdosage occur [1].
What restart dose does the label give?
After cardiovascular symptoms, the label says to restart at a lower dose and does not name a number. Its initial doses are 25 mcg once daily for adults and 5 mcg once daily for elderly people or people with underlying cardiac disease [1].
How fast do effects change after a dose change?
The label gives a T3 biological half-life of about 2.5 days, onset of activity within a few hours and maximum response within 2 or 3 days [1].
Do guidelines recommend T3 for people who still feel unwell on levothyroxine?
The ATA 2014 guideline recommended against routine T4/T3 combination therapy [2]. A 2023 UK consensus says a trial may be warranted for some patients with confirmed overt hypothyroidism and persistent symptoms despite optimized levothyroxine, as a shared decision [3].
Does Cytomel help with weight loss?
No. The label has a boxed warning that thyroid hormones including Cytomel should not be used for obesity or weight loss. In euthyroid people, doses within daily hormonal requirements are ineffective for weight reduction, and larger doses can be serious or life-threatening, especially with sympathomimetic amines [1].

References

  1. U.S. National Library of Medicine, DailyMed. Cytomel (liothyronine sodium) tablets prescribing information. Cytomel (liothyronine sodium) tablets label
  2. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-751. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement
  3. Ahluwalia R, Baldeweg SE, Boelaert K, Chatterjee K, Dayan C, Okosieme O, et al. Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement. Clin Endocrinol (Oxf). 2023;99(2):206-216. Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement
  4. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2006;91(7):2592-9. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials
  5. Jonklaas J, Bianco AC, Cappola AR, Celi FS, Fliers E, Heuer H, et al. Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. Thyroid. 2021;31(2):156-182. Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document
  6. Bahl S, Taylor PN, Premawardhana LD, Stedman M, Heald A, Dayan CM, et al. Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2025;110(11):3278-3288. Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis
Evidence overview for reviews liothyronine: Cytomel (Liothyronine) Regret, Stopping, and Restarting: What Real Patients and Clinicians Say